Hot News

Fosun Pharma Releases 2018 Annual Results：Adhere to Innovation and Internationalization with Steady Growth in Pharmaceutical Manufacturing and R&D segment Revenue RMB 24.92 billion, up 34.45% YOY Cash flows from operating activities RMB 2.95 billion, up 14.34% YOY R&D Investment RMB 2.51 billion, up 63.92% YOY

On 25 March 2019, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (Fosun Pharma, stock code：600196.SH，02196.HK), a leadin...

Hot News

Fosun Pharma Has Opened a New Era for Biosimilar in China Henlius Receives NMPA Approval for Its First Product HLX01

Recently, HLX01 (rituximab injection), independently developed by Shanghai Henlius Biotech, Inc.(Henlius), Fosun Pharma’...

Hot News

Conference Announcement | FOR A MALARIA-FREE WORLD Fosun Pharma at the 7th MIM Pan African Malaria Conference

The 7th Multilateral Initiative on Malaria (MIM) Pan-African Malaria Conference (Hereinafter referred to as MIM) will...

Hot News

Strengthening Innovation and R&D, Deepening Internationalization Strategy

Fosun Pharma Recorded Revenue of RMB18,534 1million in 2017, up by 26.69% YoY Net profit attributable to shareholders of the listed company after deduction of non-recurring profit or loss Recorded RMB2,346 million, up by 12.10% YoY R&D Investment amounted to RMB1,529 million, up by 38.26% YoY